- Home
- LSPD vs GLUE Comparison
LSPD vs GLUE Comparison
Compare LSPD & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSPD | GLUE |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LSPD | GLUE |
|---|---|---|
| Price | $8.84 | $16.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 4 |
| Target Price | $13.40 | ★ $28.25 |
| AVG Volume (30 Days) | 629.3K | ★ 786.6K |
| Earning Date | 02-05-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | $15.43 | N/A |
| Revenue Next Year | $11.10 | $16.71 |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $7.34 | $3.50 |
| 52 Week High | $14.34 | $25.77 |
Technical Indicators
Market Signals| Indicator | LSPD | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 37.36 | 36.78 |
| Support Level | $8.48 | $15.21 |
| Resistance Level | $9.71 | $16.66 |
| Average True Range (ATR) | 0.33 | 0.92 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 11.79 | 19.91 |
Price Performance
Historical ComparisonAbout LSPD Lightspeed Commerce Inc. Subordinate Voting Shares
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, United Kingdom, Australia, and other countries. It derives a majority of its revenue from the United States.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.